Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REP 2139-Ca + Pegasys in Chronic Hepatitis B
NCT02726789Phase 2Completed
- Sponsor
- Replicor Inc.
- Start
- Oct 2012
- Primary completion
- Sep 2016
- Modality
- Antisense DNA, Polymer-based Nanoparticles, Small Interfering RNA (siRNA)
01
Overview
Phase 2, open-label, single-arm trial of REP 2139-Mg in Chronic Hepatitis B (CHB), sponsored by Replicor Inc. Primary endpoint: Number of Patients Experiencing Treatment Emergent Laboratory Test Abnormalities or Adverse Events at 48 weeks. Started Oct 2012; status: completed.
02
Drugs
REP 2139-Mg
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02726789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02726789.